Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.66 |
| ▸ | HPGD | P15428 | 7/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | CASP1 | P29466 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | PNP | P00491 | 2/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23323358 | 0.85 | KMT2A (0.52) | KDM4EHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL6348563 | 0.83 | ALDH1A1 (0.62) | KDM4EHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL1947719 | 0.83 | KMT2A (0.59) | KDM4EHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL6093318 | 0.82 | ALDH1A1 (0.56) | KDM4EHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL1944329 | 0.82 | TLR7 (0.49) | KDM4EHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL1946617 | 0.81 | HPGD (0.59) | KDM4EHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL6350010 | 0.80 | ALDH1A1 (1.00) | KDM4EHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL5827636 | 0.79 | TLR7 (0.49) | KDM4EHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL10769766 | 0.77 | ALDH1A1 (0.50) | KDM4EHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL18207662 | 0.77 | MEN1 (0.55) | KDM4EHPGDKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8324224-B2 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324224-B2 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324224-B2 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110257127-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257127-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257127-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-1444233-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD PALO ALTO INC (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-1636232-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA Bioscience nv (BE) | 2006-03-22 | — | — | EP | disclosed |
| US-6977300-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050261316-A1 | A2B Adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050101778-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050038045-A1 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2004104005-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2004-12-02 | — | — | WO | disclosed |
| US-6825349-B2 | PURINE DERIVATIVES FOR TREATMENT OF GASTROINTESTINAL DISORDERS, IMMUNOLOGICAL DISORDERS, NEUROLOGICAL DISORDERS | CV THERAPEUTICS INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1479682-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA Bioscience nv (BE) | 2004-11-24 | — | — | EP | disclosed |
| US-20030229106-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030139428-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257127-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | KDM4E 4389/4885HPGD 718/4885KMT2A 2668/4885 |
| US-20050038045-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | KDM4E 4389/4885HPGD 718/4885KMT2A 2668/4885 |
| US-20050101778-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | KDM4E 4126/4885HPGD 645/4885KMT2A 2260/4885 |
| US-20030139428-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | KDM4E 4096/4885HPGD 899/4885KMT2A 2479/4885 |
| US-20030229106-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | KDM4E 4096/4885HPGD 899/4885KMT2A 2479/4885 |
| US-20050261316-A1 | A2B Adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | KDM4E 4389/4885HPGD 718/4885KMT2A 2668/4885 |
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | KDM4E 4389/4885HPGD 718/4885KMT2A 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.